Coherus BioSciences/CHRS

$2.00

0%
-
1D1W1MYTD1YMAX

About Coherus BioSciences

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.

Ticker

CHRS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Dennis Lanfear

Employees

306

Headquarters

Redwood city, United States

CHRS Metrics

BasicAdvanced
$242.34M
Market cap
-
P/E ratio
-$2.56
EPS
0.53
Beta
-
Dividend rate
$242.34M
0.53238
$8.34
$1.43
3.32M
1.434
1.245
-4.77%
-42.85%
-74.34%
0.942
21.89%
31.8%
-18.54%

What the Analysts think about CHRS

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 7 analysts.
421.5% upside
High $23.00
Low $4.00
$2.00
Current price
$10.43
Average price target

CHRS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-86.99% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$91.5M
22.82%
Net income
$-79.6M
101.01%
Profit margin
-86.99%
63.67%

CHRS Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 420.28%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.75
-$0.38
-$0.27
-$0.62
-
Expected
-$0.57
-$0.48
-$0.27
-$0.12
-$0.24
Surprise
31.02%
-21.6%
-1.7%
420.28%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Coherus BioSciences stock?

Coherus BioSciences (CHRS) has a market cap of $242.34M as of April 19, 2024.

What is the P/E ratio for Coherus BioSciences stock?

The price to earnings (P/E) ratio for Coherus BioSciences (CHRS) stock is 0 as of April 19, 2024.

Does Coherus BioSciences stock pay dividends?

No, Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Coherus BioSciences dividend payment date?

Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders.

What is the beta indicator for Coherus BioSciences?

Coherus BioSciences (CHRS) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Coherus BioSciences stock price target?

The target price for Coherus BioSciences (CHRS) stock is $10.43, which is 421.5% above the current price of $2. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Coherus BioSciences stock

Buy or sell Coherus BioSciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing